Van ECK Associates Corp Sells 2,674 Shares of DexCom, Inc. (NASDAQ:DXCM)

Van ECK Associates Corp cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,959 shares of the medical device company’s stock after selling 2,674 shares during the quarter. Van ECK Associates Corp’s holdings in DexCom were worth $2,229,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC boosted its position in shares of DexCom by 11.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after purchasing an additional 115 shares in the last quarter. CX Institutional bought a new stake in shares of DexCom during the fourth quarter valued at approximately $286,000. abrdn plc boosted its position in shares of DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock valued at $47,221,000 after purchasing an additional 66,348 shares in the last quarter. Cerity Partners LLC boosted its position in shares of DexCom by 5,791.0% during the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock valued at $57,574,000 after purchasing an additional 456,097 shares in the last quarter. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in DexCom in the fourth quarter worth $57,000. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DXCM has been the topic of several analyst reports. Royal Bank of Canada initiated coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Canaccord Genuity Group boosted their target price on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. UBS Group boosted their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, Citigroup boosted their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $141.67.

DexCom Stock Up 0.3 %

DexCom stock opened at $130.10 on Wednesday. The stock has a market cap of $51.74 billion, a PE ratio of 83.94, a price-to-earnings-growth ratio of 2.19 and a beta of 1.23. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00. The stock has a fifty day moving average of $132.67 and a 200 day moving average of $121.11.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, sell-side analysts predict that DexCom, Inc. will post 1.78 EPS for the current year.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the sale, the executive vice president now owns 68,682 shares in the company, valued at $9,618,227.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 190,004 shares of company stock worth $25,610,270. 0.41% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.